2022 annual financial data
Karyopharm Therapeutics 2022 Operating margin
Direct answer
Operating margin was -90.53%.
Operating income was -142,202,000 USD and net income was -165,291,000 USD.
Operating cash flow was -149,554,000 USD.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 157,074,000 USD
- Operating income
- -142,202,000 USD
- Net income
- -165,291,000 USD
- Operating cash flow
- -149,554,000 USD